Loading clinical trials...
Loading clinical trials...
VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent
Conditions
Interventions
VERU-111
Enzalutamide, Abiraterone
Locations
40
United States
Alaska Oncology and Hematology, LLC.
Anchorage, Alaska, United States
Urology Associates of Southern Arizona
Tucson, Arizona, United States
Arizona Urology Specialists
Tucson, Arizona, United States
Tower Urology
Los Angeles, California, United States
University of California, Irvine
Orange, California, United States
West Coaster Center Urology
Oxnard, California, United States
Start Date
June 24, 2021
Primary Completion Date
May 4, 2023
Completion Date
May 4, 2023
Last Updated
February 5, 2024
NCT06190899
NCT07005154
NCT06705686
NCT06842498
NCT05489211
NCT07476001
Lead Sponsor
Veru Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions